Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit.

"Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: L.C. has disclosed that he has received consulting fees from AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Teva, University of Arizona, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial or scientific scoping research Speaker: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva and CME activities organised by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies Stocks (small number of shares of common stock): Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased >10 years ago, stock options: Reviva Royalties: Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics). E.F.-E. served as PI for the NIHR-HTA funded ATLANTIS study. C.P., T.R.E.B. and O.R. have nothing to declare."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The Prescribing Observatory for Mental Health is funded solely through subscriptions from member healthcare organisations (principally NHS Trusts)."